One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: PR Newswire
FinancialNewsMedia.com News Commentary - Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.PALM BEACH, Fla., Nov. 17, 2022 /PRNewswire/ -- Research and development is still focused on trying to help understand the acute infection 9itself and the effects of long COVID as well. As debilitating as it can be to contract COVID, many people are just as concerned about experiencing long COVID symptoms. In fact, according to the CDC, nearly one in five Americans who have been infected with the virus still have long COVID. An article on Yahoo.com discussed the treatments for Long COVID, saying: "Long COVID is still a mysterious condition following COVID infection that spans more than 100 different symptoms. This is what makes it so challenging to diagnose and treat. Some of the more common symptoms include: Brain fog, extreme fatigue, racing heart, ringing in the ears, profound weakness, intestinal upset like diarrhea and
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Sees Positive Results For Macular Degeneration Therapy [Yahoo! Finance]Yahoo! Finance
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD [Yahoo! Finance]Yahoo! Finance
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDPR Newswire
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy DaysPR Newswire
- REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
RGNX
Earnings
- 2/27/24 - Miss
RGNX
Sec Filings
- 3/21/24 - Form 4
- 3/18/24 - Form 4
- 3/11/24 - Form 8-K
- RGNX's page on the SEC website